Allostatic Load Effects on Cortical and Cognitive Deficits in Essentially Normotensive, Normoweight Patients with Schizophrenia.
Schizophrenia
allostatic load
chronic stress
cognitive function
cortical thickness
Journal
Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760
Informations de publication
Date de publication:
08 07 2021
08 07 2021
Historique:
pubmed:
28
1
2021
medline:
17
12
2021
entrez:
27
1
2021
Statut:
ppublish
Résumé
Reduced cortical gray matter integrity and cognitive abilities are among core deficits in schizophrenia. We hypothesized that higher allostatic load (AL) that accounts for exposure to chronic stress is a contributor to structural and cognitive deficits in schizophrenia. One hundred and sixty-seven schizophrenia patients who were on average with normal weight, normal systolic, and diastolic blood pressure and 72 healthy controls were enrolled in the study. Group differences in subclinical cardiovascular, metabolic, immune, and neuroendocrine biological markers as indexed by AL and contribution of AL components to the structural and cognitive deficits in schizophrenia were explored. Compared with controls, schizophrenia patients who were normotensive, normoweight, and had low total cholesterol levels still had significantly higher AL mainly due to lower high-density lipoprotein cholesterol and higher heart rate, waist-hip ratio, hemoglobinA1c, hypersensitive C-reactive protein, and overnight-urine cortisol levels. Patients also had decreased whole-brain mean cortical thickness, and lower cognition assessed by the MATRICS consensus cognitive battery. AL was inversely correlated with mean cortical thickness and cognition in schizophrenia, while none of these relationships existed in controls. Mediation analyses showed the effect of AL on cognitive deficits in schizophrenia was significantly mediated by cortical thinning, and the most significant mediating cortical area was the left superior frontal gyrus. Cortical thickness may act as a mediator between AL and cognitive deficits in schizophrenia. Early intervention strategies to reduce cortical thinning and cognitive dysfunction in schizophrenia should target specific aspects of their high AL in addition to weight gain, hypertension and high cholesterol levels.
Identifiants
pubmed: 33501486
pii: 6120669
doi: 10.1093/schbul/sbaa196
pmc: PMC8266595
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1048-1057Subventions
Organisme : NIMH NIH HHS
ID : R01 MH116948
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB015611
Pays : United States
Organisme : NIH HHS
ID : S10 OD023696
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Schizophr Res. 2019 Aug;210:73-80
pubmed: 31262574
Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4770-5
pubmed: 11287659
Schizophr Bull. 2017 Jul 1;43(4):900-906
pubmed: 28008071
Psychol Med. 2017 Apr;47(5):902-912
pubmed: 27894372
Arch Gen Psychiatry. 2000 Aug;57(8):761-8
pubmed: 10920464
Neuroscience. 2004;125(1):1-6
pubmed: 15051139
Am J Psychiatry. 2019 Oct 1;176(10):811-819
pubmed: 31256609
Acta Psychiatr Scand. 2018 Dec;138(6):581-590
pubmed: 30264457
Arch Gen Psychiatry. 2011 Sep;68(9):871-80
pubmed: 21893656
Biol Psychiatry. 2011 Mar 1;69(5):487-94
pubmed: 20951979
Br J Psychiatry. 1998 Aug;173:183
pubmed: 9850240
Behav Res Methods. 2008 Aug;40(3):879-91
pubmed: 18697684
Am J Psychiatry. 2010 Jun;167(6):686-93
pubmed: 20360319
Int J Neuropsychopharmacol. 2011 May;14(4):459-77
pubmed: 20950517
Neuroimage. 2020 Jan 1;204:116212
pubmed: 31546050
Hum Brain Mapp. 2019 Dec 1;40(17):4982-4993
pubmed: 31397949
Psychol Med. 2020 Sep;50(12):2034-2045
pubmed: 31615588
Front Immunol. 2018 Oct 10;9:2230
pubmed: 30364161
Lancet Psychiatry. 2015 May;2(5):452-464
pubmed: 26360288
Physiol Meas. 2018 Oct 30;39(11):115001
pubmed: 30222594
Schizophr Bull. 2020 Feb 26;46(2):363-373
pubmed: 31504969
Int J Geriatr Psychiatry. 2020 Jul;35(7):728-736
pubmed: 32128879
Eur J Pharmacol. 2008 Apr 7;583(2-3):174-85
pubmed: 18282566
Lancet. 2005 Sep 24-30;366(9491):1059-62
pubmed: 16182882
Front Psychiatry. 2020 Jan 09;10:937
pubmed: 31998156
Mol Psychiatry. 2016 Apr;21(4):554-64
pubmed: 26169974
JAMA Psychiatry. 2017 Mar 1;74(3):261-269
pubmed: 28097367
Schizophr Bull. 2020 Apr 10;46(3):722-731
pubmed: 31603232
Lancet Neurol. 2012 Dec;11(12):1039-47
pubmed: 23122892
FASEB J. 2020 Jan;34(1):1150-1168
pubmed: 31914623
Brain. 2006 Dec;129(Pt 12):3315-28
pubmed: 16984899
Schizophr Res. 2015 Dec;169(1-3):109-115
pubmed: 26441005
Ann N Y Acad Sci. 1999;896:30-47
pubmed: 10681886
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Endocrinology. 1985 Dec;117(6):2505-11
pubmed: 2998738
Transl Psychiatry. 2018 Nov 12;8(1):246
pubmed: 30420620
Nat Rev Neurosci. 2009 Jun;10(6):434-45
pubmed: 19401723
Biol Psychiatry. 2010 Feb 1;67(3):255-62
pubmed: 19897178
Schizophr Res. 2019 Feb;204:439-441
pubmed: 30201550
Schizophr Bull. 2016 Jan;42(1):96-124
pubmed: 26221050
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):531-8
pubmed: 18061326
Am J Psychiatry. 2010 Oct;167(10):1232-9
pubmed: 20634363
Neuroimage. 2010 Nov 15;53(3):1135-46
pubmed: 20006715
Psychoneuroendocrinology. 2017 Mar;77:105-111
pubmed: 28027496
Alzheimers Dement. 2016 Aug;12(8):890-9
pubmed: 27139841
Psychosom Med. 2017 Sep;79(7):770-776
pubmed: 28498274
Neurosci Biobehav Rev. 2014 Sep;45:183-201
pubmed: 24950476
Psychoneuroendocrinology. 2020 Oct;120:104789
pubmed: 32739647
Psychoneuroendocrinology. 2018 Apr;90:35-42
pubmed: 29427955
Arch Gen Psychiatry. 2009 May;66(5):467-77
pubmed: 19414706
Biol Psychiatry. 2004 Sep 1;56(5):301-7
pubmed: 15336511
Psychoneuroendocrinology. 2018 Oct;96:166-172
pubmed: 29980008
Horm Behav. 2010 Feb;57(2):105-11
pubmed: 19786032
Neurosci Biobehav Rev. 2020 Jan;108:694-711
pubmed: 31846655
Schizophr Bull. 2016 May;42(3):712-22
pubmed: 26834027
Schizophr Bull. 2012 Sep;38(5):1050-62
pubmed: 21436318
Psychoneuroendocrinology. 2020 May;115:104645
pubmed: 32171901
Am J Psychiatry. 2019 Jul 1;176(7):552-563
pubmed: 31164006
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223
Perspect Psychol Sci. 2013 Nov;8(6):673-5
pubmed: 25221612
Schizophr Bull. 1984;10(2):258-92
pubmed: 6729412
J Anat. 2010 Oct;217(4):324-33
pubmed: 20408906
Brain Behav Immun. 2019 Oct;81:213-219
pubmed: 31201848
Hum Brain Mapp. 2019 Aug 15;40(12):3575-3588
pubmed: 31062906
J Clin Psychiatry. 2016 Feb;77 Suppl 2:8-11
pubmed: 26919052
J Comp Neurol. 2016 Dec 15;524(18):3729-3746
pubmed: 27113541
Am J Psychiatry. 2011 May;168(5):552-3
pubmed: 21536705